Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

Osteoporosis International

Volumn 25, Issue 7, 2014, Pages 1953-1961

  Brown, J P ^a   Roux, C ^b   Ho, P R ^c   Bolognese, M A ^d   Hall, J ^c   Bone, H G ^e   Bonnick, S ^f   Van Den Bergh, J P ^g   Ferreira, I ^h   Dakin, P ^c   Wagman, R B ^c   Recknor, C ⁱ  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c AMGEN INC   (United States)

^d Bethesda Health Research Center   (United States)

^e Michigan Bone and Mineral Clinic   (United States)

^f Clinical Research Center of North Texas   (United States)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h AMGEN LTD   (United Kingdom)

ⁱ United Osteoporosis Centers   (United States)

Author keywords

Adherence; Bone mineral density; Bone turnover; Denosumab; Oral bisphosphonate; Postmenopausal osteoporosis

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; IBANDRONIC ACID; RISEDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; ETIDRONIC ACID; MONOCLONAL ANTIBODY; PEPTIDE;

ACUTE PANCREATITIS; ARTICLE; BACTERIAL INFECTION; BONE DENSITY; BONE TURNOVER; CELLULITIS; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HEART DISEASE; HIGH RISK PATIENT; HIP; HUMAN; HYPOCALCEMIA; INFECTION; LUMBAR SPINE; MULTICENTER STUDY (TOPIC); NEOPLASM; OPEN STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR DISEASE; WOUND HEALING IMPAIRMENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; BONE REMODELING; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; LUMBAR VERTEBRA; MEDICATION COMPLIANCE; META ANALYSIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; INJECTIONS, SUBCUTANEOUS; LUMBAR VERTEBRAE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84902319073     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2692-7     Document Type: Article

References (36)

1. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856-861
2. Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22:741-753
3. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
4. Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145-155
5. Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, Davies W (2012) A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int 23:1415-1424
6. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA (2010) Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 123:275-280
7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
8. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3-S13
9. Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19:1421-1429
10. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
11. Finigan J, Greenfield DM, Blumsohn A, Hannon RA, Peel NF, Jiang G, Eastell R (2008) Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women. J Bone Miner Res 23:75-85
12. Gehlbach SH, Avrunin JS, Puleo E, Spaeth R (2007) Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 18:805-810
13. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122-128
14. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767-773
15. Nevitt MC, Cummings SR, Stone KL et al (2005) Risk factors for a first-incident radiographic vertebral fracture in women > or =65 years of age: the study of osteoporotic fractures. J Bone Miner Res 20:131-140
16. WHO (2003) Adherence to long-term therapies: evidence for action. World Health Organization. http://www.who.int/chp/knowledge/publications/adherence- report/en/ Accessed 28 Oct 2013
17. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A (2012) Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 34:521-536
18. Genant HK, Engelke K, Hanley DA et al (2010) Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 47:131-139
19. Keaveny T, McClung M, Genant H et al (2014) Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Mineral Res 29:158-165
20. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS (2011) Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49:151-161
21. Simon JA, Recknor C, Moffett AH Jr et al (2013) Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause 20:130-137
22. Recknor C, Czerwinski E, Bone HG et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291-1299
23. Roux C, Hofbauer LC, Ho PR et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48-54
24. Reynolds K, Viswanathan HN, O'Malley CD et al (2012) Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates. Ann Pharmacother 46:659-670
25. Boonen S, Adachi JD, Man Z et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96:1727-1736
26. McClung MR, Boonen S, Torring O et al (2012) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27:211-218
27. Brown JP, Deal C, de Gregorio LH et al (2008) Effect of denosumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level [Abstract 1285]. J Bone Miner Res 23(Suppl S1):S80
28. Miller P, Gruntmanis U, Boonen S, Yang Y, Wagman R, Hall J, Orwoll E (2012) The effect of denosumab on bone mineral density (BMD) assessed by baseline bone turnover in men with low BMD [Abstract FR0393]. J Bone Miner Res 27(Suppl 1):S123
29. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72-81
30. Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153-161
31. Austin M, Yang YC, Vittinghoff E et al (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27:687-693
32. Seeman E, Delmas PD, Hanley DA et al (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886-1894
33. Zebaze RM, Libanati C, McClung MR, Zanchetta JR, Kendler DL, Høiseth A, Wang A, Ghasem-Zadeh A, Seeman E (2013) Denosumab reduces hip cortical porosity in women with osteoporosis [Abstract 1065]. J Bone Miner Res 28(Suppl S1):S23
34. Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ (2011) Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 49:162-173
35. Miller PD, McClung MR, Macovei L et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315-1322
36. Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765